Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.58 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903683 | 0.85 | SRC (0.70) | SRCABL1 | |
| SCHEMBL4892737 | 0.82 | SRC (0.79) | SRCABL1 | |
| SCHEMBL4898154 | 0.82 | SRC (0.72) | SRCABL1 | |
| SCHEMBL4901483 | 0.81 | SRC (0.71) | SRCABL1 | |
| SCHEMBL4904328 | 0.81 | SRC (0.67) | SRCABL1BCR | |
| SCHEMBL3227888 | 0.79 | SRC (0.75) | SRCABL1BCR | |
| SCHEMBL4904398 | 0.79 | SRC (0.68) | SRCABL1BCR | |
| SCHEMBL5259601 | 0.77 | SRC (0.53) | SRCABL1BCR | |
| SCHEMBL3213030 | 0.77 | SRC (0.82) | SRCABL1BCR | |
| SCHEMBL4900617 | 0.75 | SRC (0.81) | SRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | claimed |
| EP-1756117-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005113560-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-12-01 | — | — | WO | claimed |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-12-02 | — | — | US | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | BOSCHELLI DIANE H | 2008-03-20 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276519-B2 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1756117-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005113560-A2 | THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | SRC 1484/4885ABL1 698/4885BCR 64/4885 |
| US-20080070913-A1 | Thieno [ 3,2-b] pyridine-6-carbonitriles and thieno [2,3-b] pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, TNNI3K, PKN1 | SRC 242/4885ABL1 60/4885BCR 320/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | SRC 1586/4885ABL1 746/4885BCR 48/4885 |
| US-20040242883-A1 | Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | PKN2, PTK2B, PKN1 | SRC 189/4885ABL1 91/4885BCR 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.